Optimization of TLC method for separation and determination of ziprasidone and its impurities by Obradović, Darija et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=ljlc20
Download by: [Florida Atlantic University] Date: 11 March 2016, At: 00:52
Journal of Liquid Chromatography & Related
Technologies
ISSN: 1082-6076 (Print) 1520-572X (Online) Journal homepage: http://www.tandfonline.com/loi/ljlc20
Optimization of TLC Method for Separation and
Determination of Ziprasidone and Its Impurities
Darija Obradović, Slavica Filipić, Katarina Nikolić, Marija Čarapić & Danica
Agbaba
To cite this article: Darija Obradović, Slavica Filipić, Katarina Nikolić, Marija Čarapić &
Danica Agbaba (2016): Optimization of TLC Method for Separation and Determination of
Ziprasidone and Its Impurities, Journal of Liquid Chromatography & Related Technologies, DOI:
10.1080/10826076.2016.1163183
To link to this article:  http://dx.doi.org/10.1080/10826076.2016.1163183
Accepted author version posted online: 10
Mar 2016.
Submit your article to this journal 
View related articles 
View Crossmark data
  1 
Optimization of TLC Method for Separation and Determination of Ziprasidone and 
Its Impurities 
 
Darija Obradović1, Slavica Filipić1, Katarina Nikolić1, Marija Čarapić2, Danica Agbaba1 
 
1
University of Belgrade, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, 
Belgrade, Serbia, 
2
Medicines and Medical Devices Agency of Serbia, Belgrade, Serbia 
 
Address correspondence to Danica Agbaba, Department of Pharmaceutical Chemistry, 
Faculty of Pharmacy, University of Belgrade, Vojvode Stepe 450, 11000 Belgrade, 
Serbia. E-mail: danica@pharmacy.bg.ac.rs 
 
Abstract 
A thin-layer chromatographic method for simultaneous determination of ziprasidone and 
its main impurities was developed and validated. Separation of the examined compounds 
was performed on chromatographic plates precoated with silica gel 60F254 and using 
toluene-methanol-glacial acetic acid, 7.5:0.5:0.5 (v/v/v) as mobile phase. Ascending 
development mode was performed in the twin-trough chromatographic chamber, which 
was presaturated with mobile phase vapors for 15 min. The developed chromatographic 
plates were dried in air and densitometrically scanned at the wavelengths of 250 and 320 
nm. Regression coefficient (r≥0.992), recovery (94.94-106.70%), limit of quantification 
of impurities (25 ng band
-1
 equivalent to the 0.14% impurity level), and robustness were 
validated and found satisfactory. The developed method is convenient for quantitative 
analysis and the purity screening of ziprasidone in pharmaceutical formulations. 
KEYWORDS: impurities, method validation, ziprasidone, quantitation, TLC, 
pharmaceuticals 
 
INTRODUCTION 
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Ziprasidone (ZP) belongs to the second generation of so-called atypical antipsychotic 
drugs, having the G protein-coupled receptor (GPCR) binding profile. It is a high-affinity 
antagonist at 5-HT2A, 5-HT2C and D2 as well as at adrenergic 1/ 2 and histamine H1 
receptors. It is used for the treatment of schizophrenia and bipolar disorders, with 
relatively low incidence of extrapyramidal side effects.
[1,2] 
 
Ziprasidone is a benzisothiazolyl piperazine compound that exists as a white crystalline 
solid with a very poor aqueous solubility. The pKa values of the two ionisable functional 
groups in the molecule are 8.4 and 13.3, respectively. Even after having been on the 
market for more than fourteen years now, there is still a limited data on investigation of 
the assay and purity profile of ziprasidone in raw materials and pharmaceuticals. 
Determination of ziprasidone in pharmaceutical formulations has been performed by 
CE,
[3]
 NP-HPTLC and RP-HPTLC.
[4]
 An HPLC method was reported for the 
determination of ziprasidone and its five impurities,
[5]
 and several stability-indicating 
methods for the determination of ziprasidone were reported using HPLC,
[6,7]
 UPLC,
[8,9]
 
TLC,
[7]
 and spectrofluorimetry.
[10] 
 
Reactivity of the alpha position of the benzoxindol moiety in the molecule of ziprasidone 
contributes to the instability of the molecule and to the formation of impurities and 
degradation products. The methylene moiety next to the lactam carbonyl is susceptible to 
nucleophiles and it can easily form an oxidative degradant (Impurity II; Figure 1). The 
carbonyl group in Impurity II is more reactive than a regular ketone group, owing to its 
activation by the neighboring lactam carbonyl group. Thus the oxidative degradant 
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(Impurity II) can be involved in reaction of aldol condensation with molecule of 
ziprasidone when new degradant is formed
[11]
 (Impurity III; Figure 1). This reaction was 
observed in an injectable formulation containing sulfobutyl ether -cyclodextrin 
(SBE CD) as a solubilizer of ziprasidone. Interaction of the cyclodextrin side chain with 
ziprasidone may facilitate oxidative degradation and a subsequent aldol condensation 
with another ziprasidone molecule.
[12]
 A degradant which is formed at an ambient 
temperature under the influence of the daylight in the solid state ziprasidone is a product 
of the side reaction of benzisothiazol at the alpha position of the benzoxindol moiety of 
ziprasidone (Impurity V; Figure 1). Apart from the above mentioned impurities, the 
monographs of ziprasidone in the European Pharmacopoeia (EP)
[13]
 and the United States 
Pharmacopoeia (USP),
[14] 
and the ziprasidone manufacturers require testing the residues 
of the ziprasidone synthesis precusors (Impurity I and Impurity IV, respectively; Figure 
1). Photostability of ziprasidone and photoisomerisation of the benzisothiazole moiety of 
ziprasidone were investigated by means of UHPLC-DAD/ESI-Q-TOF
[15] 
and LC-MS,
[16]
 
respectively. So far, only one paper proposed a validated HPLC method for the 
determination of ziprasidone and its impurities in the pharmaceuticals,
[5]
 while the other 
papers have reported on determination of ziprasidone in the presence of impurities 
resulting from the stability-indicating procedures.
[6-10]
 A stability indicating thin-layer 
chromatography was reported for the determination of ziprasidone in the presence of the 
synthesis precursors (Impurities I and IV).
[7] 
 
No reports are available on the thin-layer chromatographic method for the purity 
assessment of ziprasidone in pharmaceuticals, which has prompted us to develop and 
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validate an alternative TLC method for the simultaneous determination of ziprasidone 
and its impurities using instrumental planar chromatography. 
 
EXPERIMENTAL 
Materials 
Ziprasidone, (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-
dihydro-2H-indol-2-one); Impurity I (3-(1-piperazinyl)-1,2-benzisothiazole; Impurity 
II (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2H-indol-
2,3-dione); Impurity III (5,5’-bis[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-
6,6’-dichloro-1,1’,3,3’-tetrahydro-3-hydroxy-[3,3’-bi-2H-indole]-2,2’-dione); Impurity 
IV (6-chloro-5-(2-chloroethyl)-1,3-dihydro-2H-indol-2-one) and Impurity V (3-(1,2-
benzisothiazol-3-yl)-5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-
dihydro-2H-indol-2-one) were kindly supplied by Pfizer Inc. (Groton, CT, USA). Zeldox 
(ziprasidone hydrochloride capsules, 40 mg, bach 710308135 and bach D10345242) and 
Zeldox (ziprasidone mesylate powder for the solution for injection 20 mg mL
-1
, bach 
8274917) were manufactured by Pfizer (Illertissen, Germany, and Poce-sur-Cisse, 
France, respectively). All other reagents, i.e., toluene (POCH,Gliwice, Poland), methanol 
(J.T.Baker B.V., Deventer, Holland), concentrated hydrochloric acid and glacial acetic 
acid (Merck, Darmstadt, Germany) were of the analytical purity grade. 
 
Solutions 
Standard Solutions 
D
ow
nl
oa
de
d 
by
 [F
lor
ida
 A
tla
nti
c U
niv
ers
ity
] a
t 0
0:5
2 1
1 M
arc
h 2
01
6 
  5 
Stock solutions of ziprasidone (1 mg mL
-1
) and impurities I, II and IV (0.15 mg mL
-1
) 
were prepared in methanol, while impurities III (0.15 mg mL
-1
) and V (0.15 mg mL
-1
) 
were disolved in the mixture of methanol and HCl (0.001 mL HCl in 10 mL methanol). 
Solution of Impurity III was stored for one day at 4°C, and those of ziprasidone and the 
other impurities for 7 days, according to the earlier established stability periods valid for 
these solutions. Due to photosensitivity of ziprasidone, all the solutions were protected 
from light by storage in amber bottles, in order to prevent them from photodegradation.
[5] 
 
Six different solutions for the calibration curves were prepared by diluting the stock 
solutions with metanol in order to obtain concentrations from 0.01 to 0.07 mg mL
-1 
for 
ziprasidone, from 0.0025 to 0.015 mg mL
-1 
for impurities I, III, IV, and V, and from 
0.0035 to 0.02 mg mL
-1 
for impurity II. The 10-µL aliquots of each solution were applied 
on to the plates, which was equivalent to the ziprasidone amounts from 100 to 700 ng, the 
impurity I, III, IV, and V amounts from 25 to 150 ng, and the impurity II amounts from 
35 to 200 ng. 
 
Sample Solutions 
The contents of ten capsules of ziprasidone were weighed and mixed. The quantity of the 
mixed content equivalent to 18 mg ziprasidone and the quantity of the powder for the 
solution for injection equivalent to 18 mg ziprasidone were transferred to the 10-mL 
volumetric flasks, the entity was ultrasonicated in the 6 mL solvent (0.001 mL HCl in 10 
mL methanol) for 10 min, and then manually shaked for 15 more minutes. The solutions 
were made up to 10 mL with the same solvent, and then centrifuged at 3000 U/min for 15 
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min. The obtained supernatants were filtered through the 0.45-mm pore size membrane 
filter (Millipore). For an assay of the impurities, the 10-µL aliquots of the filtrates were 
applied to the chromatographic plates. For an assay of ziprasidone, the filtrated 
supernatants were diluted with methanol to the ziprasidone concentration of 0.5 mg mL
-1
 
and the 1-µL aliquots of these soultions were applied to the chromatographic plates. 
 
Chromatography 
Thin-layer chromatographic analyses were performed on the 10 cm  12 cm plates cut 
from the 20 cm  20 cm aluminium baked plates, precoated with silica gel 60F 254 
(Merck, Darmstadt, Germany). Standard and pharmaceutical preparation samples were 
applied 10 mm above the lower edge of the plate, using the Linomat 5 application device 
(Camag, Muttenz, Switzerland). Samples were applied bandwise at the 6-mm band width, 
with an application rate of 10 000 nL
s-1
. An ascending development mode at ambient 
temperature was performed to the distance of 119 mm in the twin-trough TLC chamber 
presaturated for 15 min with mobile phase (toluene-methanol-glacial acetic acid, 
7.5:0.5:0.5 v/v/v). After the development, the chromatographic plates were dried for 30 
min at ambient air and once again developed to the distance of 119 mm in the freshly 
prepared mobile phase of the same composition as before, after the 15-min chamber 
presaturation. The dried chromatographic plates were scanned at the wavelengths of 250 
and 320 nm by means of the Camag TLC Scanner II in the reflectance/absorbance mode. 
 
RESULTS AND DISCUSSION 
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Significant difference in polarity of ziprasidone and its impurities has an impact on their 
retention, so that the official pharmacopoeial methods 
[13,14]
 use two liquid 
chromatographic systems, one for the separation and purity assay of the early eluting 
impurities I and II, and the other for the late eluting impurities III and V. In our earlier 
investigations, we modeled the quantitative structure-retention relationship of the liquid 
chromatographic separation of ten compounds structurally related to ziprasidone, i.e., its 
impurities and metabolites,
[17]
 and developed a single liquid chromatographic system for 
the separation and purity assay of ziprasidone and its five impurities.
[5]
 One report 
described the development and validation of the HPLC and TLC methods for the 
determination of ziprasidone in the presence of three degradation products supplied by 
the manufacturer.
[7]
 The thin-layer chromatographic separation of ziprasidone and its 
degradants was carried out on the aluminium-backed sheets precoated with silica gel 
60F254 using chloroform-methanol-glacial acetic acid (7.5:0.5:0.45, v/v/v) as mobile 
phase. Using the same chromatographic system, in our present preliminary study we 
obtained separation of impurities I and II from ziprasidone, impurity III remained on the 
start line, and impurities IV and V co-eluted. Due to the toxicity of the halogenated 
aliphatic hydrocarbons (e.g., chloroform), Directive 1999/45/EC 
[18] 
recommends 
avoiding its use. Based on the solvent selectivity properties clustered in the Snyder’s 
solvent selectivity triangle with chloroform belonging to group VIII, we replaced it with 
two alternative solvents from the closest group VII, benzene and toluene. The satisfactory 
resolution of all investigated compounds was obtained with the mixture benzene-
methanol-glacial acetic acid (6.3:0.5:045, v/v/v), yet due to the same safety reason, 
benzene had to be replaced by toluene. This second replacement needed minor 
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modification of the mobile phase component ratio and the final composition of toluene-
methanol-glacial acetic acid (7.5:0.5:0.5 v/v/v) resulted in good separation of all 
components. The migration distances were 18.9  0.37 mm, 27.7 0.28   mm, 30.5 0.32 
mm, 41.7 0.45 mm, 58.42 0.36 mm and 69.8 0.86 mm, for impurity III, impurity I, 
impurity II, ziprasidone, impurity V and impurity IV, respectively. The elution order of 
the separated compounds was driven by an increasing lipophilicity thereof (the logP 
values for impurity I, impurity II, ziprasidone, and impurity V were equal to 3.0, 4.26, 
4.67, and 7,44, respectively). Lipophilicity was calculated with use of the Chem Draw 
Ultra program (Cambridge, MA, USA). Exceptions in the elution order were Impurity III 
with the highest logP value (8.51) and Impurity IV with the lowest logP value (2.24). 
Impurity III with two piperazine moieties in its structure strongly binds to the silanol 
groups on the silica gel surface, which results in the lowest migration distance. Impurity 
IV which lacks piperazine moiety has the weakest retention and hence, the highest 
migration distance. Densitometric scans of the TLC chromatograms are shown in Fig 2. 
Testing the elaborated mobile phase upon the HPTLC and TLC glass-backed plates, it 
was shown that no better resolution was obtained than on the aluminium-backed and 
silica gel 60F precoated ones, which were then used for further validation of the 
developed method. 
 
The in situ spectra were recorded for all investigated substances and they are shown in 
Fig. 3. Quantitative evaluation of impurities I, II, III and ziprasidone were performed at 
the wavelength λ = 320 nm, and that of impurities IV and V, at the wavelength λ = 250 
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nm. When scanning the chromatograms at 320 nm, the lower baseline noise was 
observed.  
 
The response (peak area) was proportional to the concentration (the amount applied to the 
plate) over the entire concentration ranges tested. The results referring to the elaborated 
calibration curves for ziprasidone and its five impurities are summarized in Table 1. 
 
An effect of larger amounts of ziprasidone on the peak shape and the resolution of the 
impurities also had to be evaluated in order to avoid systematic errors. Therefore the 
accuracy of the method was estimated by determination of all impurities in the presence 
of ziprasidone. It was observed that high quantitative excess of ziprasidone results in poor 
resolution of Impurity I and II after the second development run and therefore the purity 
assay for Impurities I, II, III, and ziprasidone was performed after the first development 
run. Quantitative evaluation of Impurity IV and V was performed after the repeated 
second development run using the same mobile phase, which provided better resolution 
of these two impurities. A content of the capsules of ziprasidone (1.80 mg mL
-1
) were 
spiked with impurities I, III, IV and V at the concentrations of 0.0029, 0.0036, and 
0.0054 mg mL
-1
 each (corresponding to 0.16, 0.20, and 0.30%), and with Impurity II at 
the concentrations of 0.0043, 0.0054, and 0.0081 mg mL
-1
 (corresponding to 0.24, 0.30, 
and 0.45%). Higher values of the limits for Impurity II (oxidation product of ziprasidone) 
were required due to the manufacturer's specification for dosage formulations. 
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Densitograms obtained from the spiked samples of ziprasidone are shown in Fig. 4. No 
interference from the capsules excipients and the residual impurities were observed. 
Calculated recoveries were plotted against the expected values (corresponding to the 
standards without ziprasidone). Recoveries and the relative standard deviation values for 
all impurities were acceptable for a purity method (Table 2). The accuracy acceptance 
criteria for the drug impurity testing depend on impurity levels. For the levels below 
0.50% and those above 0.50%, the recovery rates of 80-120% and 90-110%, respectively, 
and the RSD values of 10% and 5%, respectively, are acceptable.
[19] 
 
The repeatability of the method was assessed by running replicate applications (n= 6) of 
ziprasidone and Impurities I–V at the three concentrations, with the relevant statistical 
parameter and the results are listed in Table 3. 
 
The limit of detection (LOD) and the limit of quantification (LOQ) were determined by 
fitting the back-calculated inter-day standard deviation for each calibration standard. The 
y-intercept was equal to SD0 (the estimated standard deviation at a zero concentration). 
The LOD was defined as 3SD0, and the LOQ was defined as 10SD0. The LOD values for 
Impurities I–V were established as equal to 7.1, 8.6, 8.4, 2.5, and 11.0 ng, respectively 
(equivalent to the percentage impurity levels of 0.04, 0.05, 0.08, 0.01, and 0.06%, 
respectively). The LOQ values for Impurities I–V were established as equal to 23.7, 28.0, 
28.0, 8.5, and 36.7 ng, respectively (equivalent to the percentage impurities levels of 
0.13, 0.16, 0.27, 0.05, and 0.20%, respectively). The experimentally obtained LOQ 
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values for Impurities I-V were equal to 25 ng per band (corresponding with the impurity 
level of 0.14%). 
 
Robustness is a measure of the capacity of the method to remain unaffected by small yet 
deliberate variations of the method working parameters, and it is an indications of the 
reliability of the method.
[20,21]
 In the course of the robustness tests, the effects of different 
amounts of toluene (± 3%) and acetic acid (± 2%) in mobile phase, and differences in the 
developing distances (11 and 13 cm) and the band widths (5 and 7 mm) were examined. 
Based on the obtained results, no significant resolution changes between ziprasidone and 
its impurities was observed, showing that the proposed method remains unafected by 
small variations of experimental conditions. 
 
The method was used to screen three samples of ziprasidone, i.e., the Zeldox® powder 
for the solution for injection (20 mg mL
-1
) with the expired validity date (August, 2011), 
the Zeldox® capsules (40 mg, batch 710308135) with the expired validity date (August, 
2011), and the Zeldox® capsules (40 mg, batch D10345242) valid until September, 2017. 
The chromatograms of the tested samples are shown in Fig. 4. The contents of 
ziprasidone in the capsule, batch 710308135, in the sample powder for the solution (both 
samples with the expired validity dates), and in the valid capsules, batch D10345242, 
were established as equal to 98.8±0.62%, 99.6±0.54%, and 97.7±0.57%, respectively, 
and in that way all three formulations met the requirements of label declaration. In each 
case, the content of impurities was below of the LOQ value, i.e., below 0.14%. 
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CONCLUSION 
The results obtained suggest that TLC is an efficient method for the separation and 
quantitative determination of ziprasidone and its main impurities. The method is sensitive 
at the ng level, as well as its precision and reproducibility is satisfactory. The simple 
chromatographic system can be used as an alternative method for the purity screening of 
ziprasidone in pharmaceutical formulations. 
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Table 1. The parameters a and b of the calibration curve (y = ax + b) and the respective 
numerical values of standard deviation (SD) and correlation coefficient (r) for standard 
samples of ziprasidone and its impurities I, II, III, IV, and V 
Compound Concentration 
range ng band
-1
 
a b SD r 
Ziprasidone 100-700 1.030 60.158 5.779 0.9996 
Impurity I 25-150 2.507 93.950 5.934 0.9988 
Impurity II 35-200 1.600 29.837 4.574 0.9992 
Impurity III 25-150  2.236 41.530 6.260 0.9925 
Impurity IV 25-150 3.237 9.567 2.756 0.9998 
Impurity V 25-150 8.030 -305.892 29.448 0.9968 
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Table 2. The parameters which characterize the accuracy of the method for standard 
samples of ziprasidone and its impurities I, II, III, IV, and V 
Compound Level (%) Mean recovery (%) 
n=3 
RSD (%) 
Ziprasidone 80 99.50 1.50 
 100 99.80 1.30 
 120 95.75 0.95 
Impurity I 0.16 95.88 3.41 
 0.20 97.59 3.94 
  0.30 94.94 3.10 
Impurity II 0.24 97.12 2.90 
 0.30 96.64 3.97 
 0.45 98.31 2.76 
Impurity III 0.16 102.58 8.71 
 0.20 97.16 5.35 
 0.30 105.30 7.42 
Impurity IV 0.16 103.77 2.23 
 0.20 104.33 3.27 
 0.30 96.84 5.05 
Impurity V 0.16 103.40 1.86 
 0.20 100.07 1.85 
 0.30 106.66 1.84 
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Table 3. The parameters which characterize the precision of the method (n=6) for 
standard samples of ziprasidone and its impurities I, II, III, IV, and V 
Amount 
ng band
-1
 
Ziprasidone 
RSD (%) 
Impurity I 
RSD (%) 
Impurity II 
RSD (%) 
Impurity III 
RSD (%) 
Impurity IV 
RSD (%) 
Impurity V 
RSD (%) 
100 1.41      
300 0.81      
500 0.41      
29  2.94  8.45 2.37 2.84 
36  1.69  3.37 3.02 2.11 
54  0.97  6.83 2.67 1.99 
43   2.98    
54   3.75    
81   2.16    
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Figure 1. Chemical structures of ziprasidone and its impurities 
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Figure 2. Densitogram obtained from a test mixture of ziprasidone and its impurities 
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Figure 3. The in situ UV spectra of ziprasidone (4) and its Impurities (Impurity I (1), 
Impurity II (2), Impurity III (3), Impurity IV (6) and Impurity V (5)). 
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Figure 4. Densitograms recorded at the wavelength λ = 320 nm after the first 
development run (A) and at the wavelength λ = 250 nm after the second development run 
(B) for (a) the sample of the ziprasidone without impurities; (b,d) standards of Impurities 
I, III, IV and V corresponding to the impurity levels 0.16 and 0.20% and standard of 
Impurity II corresponding to the impurity levels 0.24 and 0.30%; (c,e) the ziprasidone 
sample spiked with Impurities I, III, IV and V corresponding to the impurity levels 0.16 
and 0.20% and standard of Impurity II corresponding  to the impurity levels 0.24 and 
0.30%; (f,g,h) Zeldox® capsules, 40 mg, batch 710308135, Zeldox® capsules, 40 mg, 
batch D10345242, and Zeldox®  powder for the solution for injection, batch 8274917. 
Peaks 1-6 correspond to Impurity III, I, II, ziprasidone, Impurity V and IV, respectively. 
At the migration distance of 48.5 mm, an unknown peak is observed. 
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